N‐myristoylation of EZH2 promotes phase separation of EZH2 with its substrate STAT3, leading to the activation of STAT3 signaling and growth of lung cancer cells, making N‐myristoylation of EZH2 a potential target for lung cancer therapy.705. This evidence concerns the gene STAT3 and lung carcinoma.